Clinical trials

The European Union Clinical Trials Register allows you to search for protocol and results information on:

interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC

clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
Clinical Trials Information System (CTIS).

The EU Clinical Trials Register currently displays 44334 clinical trials with a EudraCT protocol, of which 7366 are clinical trials conducted with subjects less than 18 years old. The register also displays information on 18700 older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).

Examples: Cancer AND drug name. Pneumonia AND sponsor name.
How to search [pdf]

Advanced Search:

Search tools

Select Country:	Select Age Range:
Select Trial Status:	Select Trial Phase:
Select Gender:
Select Date Range: to
Select Rare Disease:
IMP with orphan designation in the indication
Orphan Designation Number:
Results Status:
Clear advanced search filters

Trials with a EudraCT protocol (44,334)
Paediatric studies in scope of Art45 of the Paediatric Regulation (0)

44,334 result(s) found. Displaying page 1,349 of 2,217.

EudraCT Number: 2006-006754-10

Sponsor Protocol Number: CL3-05702-014

Start Date*: 2007-03-14

Sponsor Name:Institut de Recherches Internationales Servier

Full Title: Efficacy and safety of gliclazide MR (30 to 120 mg per day) associated or not to metformine or to an α-glucosidase inhibitor during the fast of the Ramadan in type 2 diabetic patients. A 5 to 8 mon...

Medical condition: Diabetes mellitus non insulino dependant

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	9.1		10027433	Metabolism and nutrition disorders	SOC

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: FR (Completed)

Trial results: View results

EudraCT Number: 2006-006144-55	Sponsor Protocol Number: ARD6123 [AVE0005B/2001]	Start Date*: 2007-03-14
Sponsor Name:sanofi-aventis recherche & développement
Full Title: A multicenter, open-label, single-arm, two-stage study of the efficacy and safety of AVE0005 (VEGF Trap) administered intravenously every 2 weeks in patients with platinum- and erlotinib-resistant,...
Medical condition: patients with platinum- and erlotinib-resistant, locally advanced or metastatic non-small-cell lung adenocarcinoma.
Disease:
Population Age: Adults, Elderly		Gender: Male, Female
Trial protocol: FR (Completed)
Trial results: View results

EudraCT Number: 2006-006354-98

Sponsor Protocol Number: L00074 TD 304

Start Date*: 2007-06-07

Sponsor Name:PIERRE FABRE MEDICAMENT

Full Title: “Transdermal testosterone supplementation in elderly hypogonadal men with sarcopenia: effects on muscle function, physical performance, body composition and quality of life.” A randomized, double-b...

Medical condition: ELDERLY HYPOGONADAL MEN WITH SARCOPENIA

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	9.1		10063024	Sarcopenia	LLT

Population Age: Elderly

Gender: Male

Trial protocol: FR (Completed)

Trial results: View results

EudraCT Number: 2007-002160-10

Sponsor Protocol Number: 12009A

Start Date*: 2007-11-21

Sponsor Name:H. Lundbeck A/S

Full Title: A prospective, open-label, single arm, multinational, multi-centre, flexible dose, extension study of the SCoP 99824 with sertindole for patients suffering from schizophrenia

Medical condition: Patients suffering from schizophrenia, according to the ICD-10, DSM-IV or regional classification criteria

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	9.1		10039626	Schizophrenia	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: FR (Completed)

Trial results: View results

EudraCT Number: 2014-004031-40

Sponsor Protocol Number: Version3.22.11.2014

Start Date*: 2015-04-30

Sponsor Name:Department of Respiratory Diseases, Aarhus University Hospital

Full Title: Training in intralymphatically injection technique. A realistic learning study

Medical condition: allergic rhino-conjunctivitis

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	18.0	10038738 - Respiratory, thoracic and mediastinal disorders	10039085	Rhinitis allergic	PT

Population Age: Adults

Gender: Male, Female

Trial protocol: DK (Completed)

Trial results: View results

EudraCT Number: 2014-005377-36	Sponsor Protocol Number: D1690C00025	Start Date*: 2015-02-26
Sponsor Name:AstraZeneca AB, R&D Mölndal
Full Title: An 8-week, single centre, randomized, parallel-group, double-blind, placebo controlled phase IV study to evaluate Dapagliflozin 10 mg once daily effects on insulin resistance in subjects with type ...
Medical condition: type 2 diabetes mellitus.
Disease:
Population Age: Adults, Elderly		Gender: Male, Female
Trial protocol: FI (Completed)
Trial results: View results

EudraCT Number: 2013-000906-52	Sponsor Protocol Number: SC0806-A101	Start Date*: 2015-03-24
Sponsor Name:BioArctic AB
Full Title: An Open, Randomized, Rehabilitation-controlled Study to Assess Safety, Tolerability, and Efficacy of Heparin Activated Recombinant Human Fibroblast Growth Factor 1 on a Biodegradable Device in Subj...
Medical condition: Complete Traumatic Spinal Cord Injury (TSCI)
Disease:
Population Age: Adults		Gender: Male, Female
Trial protocol: SE (Prematurely Ended) NO (Completed) EE (Prematurely Ended) FI (Completed)
Trial results: View results

EudraCT Number: 2004-001952-35	Sponsor Protocol Number: M71P1	Start Date*: 2005-09-15
Sponsor Name:Chiron S.r.l.
Full Title: A Phase IV, Observer-Blind, Randomized, Parallel Groups, Single-Center, Exploratory Clinical Study to Evaluate the Immunogenicity and Safety of Two 0.25 mL Intramuscular Doses of Agrippal™ S1, Infl...
Medical condition: Influenza
Disease:
Population Age: Infants and toddlers, Children, Under 18		Gender: Male, Female
Trial protocol: FI (Completed)
Trial results: View results

EudraCT Number: 2004-000755-41

Sponsor Protocol Number: RA/PR/3301/010/03

Start Date*: 2004-09-22

Sponsor Name:Chiesi Farmaceurtici S.p.A

Full Title: A three-month, double-blind, double dummy, parallel group, controlled study comparing the efficacy and safety between 12 µg twice daily of Formoterol-HFA and 12 µg twice daily of Formoterol-DPI (Fo...

Medical condition: Children Persistent Asthma

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	7.0		10003553		Low

Population Age: Children, Adolescents, Under 18

Gender: Male, Female

Trial protocol: CZ (Completed)

Trial results: View results

EudraCT Number: 2004-000734-36	Sponsor Protocol Number: SPD476-303	Start Date*: 2005-07-13
Sponsor Name:Shire Pharmaceutical Development Inc.
Full Title: A phase III, randomized, multi-center, open-label, 12 to 14 months extension study to evaluate the safety and tolerability of SPD476 (mesalazine) give once daily vs. twice daily for the maintenance...
Medical condition: Subject not in remission of Ulcerative Colitis (UC-DAI score of >1) at the End of Study/Early Withdrawal Visit of Study 301 or 302. Subject in remission of UC (UC-DAI<1 with a score of 0 for rectal...
Disease:
Population Age: Adults, Elderly		Gender: Male, Female
Trial protocol: CZ (Completed)
Trial results: View results

EudraCT Number: 2006-002848-28

Sponsor Protocol Number: C LF23-0121 06 02

Start Date*: 2007-04-11

Sponsor Name:FOURNIER Laboratories Ireland Ltd

Full Title: An open label, multicenter trial assessing the acceptability of a new fixed dose combination of fenofibrate 80 mg bid and metformin 1000 mg bid in patients with type 2 diabetes (T2DM) and dyslipide...

Medical condition: Patients with type 2 diabetes (T2DM) and dyslipidemia.

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	8.1		10045242	Type II diabetes mellitus	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: FR (Completed)

Trial results: View results

EudraCT Number: 2005-002381-10	Sponsor Protocol Number: 20051111	Start Date*: 2005-08-18
Sponsor Name:Dept anaesthesiology and intensive care
Full Title: Evaluation of the optimal dose of prophylactic anticoagulation with low-molecular-weight heparine administered subcutaneously to critically ill patients
Medical condition: critically ill patients with sepsis
Disease:
Population Age: Adults, Elderly		Gender: Male, Female
Trial protocol: DK (Completed)
Trial results: View results

EudraCT Number: 2005-001540-23	Sponsor Protocol Number: 309560	Start Date*: 2006-03-03
Sponsor Name:Schering Nordiska AB
Full Title: A Scandinavian, randomized, rater-blinded study of single and double-dose (2x250 mcg e.o.d.) Betaferon in patients with early secondary progressive multiple sclerosis.
Medical condition: Early Secondary Progressive Multiple Sclerosis
Disease:
Population Age: Adults, Elderly		Gender: Male, Female
Trial protocol: SE (Prematurely Ended) DK (Completed)
Trial results: View results

EudraCT Number: 2006-001536-46

Sponsor Protocol Number: N01236

Start Date*: 2006-11-14

Sponsor Name:UCB S.A.

Full Title: A multicenter, randomized, double-blind, placebo-controlled, parallel study to evaluate the efficacy and safety of brivaracetam used as adjunctive treatment for 12 weeks in adolescent and adult pat...

Medical condition: Patients with genetically ascertained Unverricht-Lundborg disease (ULD).

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	8.1		10054894	Unverricht-Lundborg disease	LLT

Population Age: Adolescents, Under 18, Adults, Elderly

Gender: Male, Female

Trial protocol: FR (Completed) FI (Completed)

Trial results: View results

EudraCT Number: 2007-003237-16

Sponsor Protocol Number: GFT505-207-1

Start Date*: 2007-08-31

Sponsor Name:GENFIT

Full Title: A Pilot study to evaluate the Efficacy and Safety of GFT505 (30 mg) orally administered for 28 days in patients with Frederickson Type IIb Dyslipidemia (Mixed Hyperlipidemia). A double blind, place...

Medical condition: Patients with Frederickson Type IIb Dyslipidemia (Mixed Hyperlipidemia).

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	9.1		10027763	Mixed hyperlipidemia	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: FR (Completed)

Trial results: View results

EudraCT Number: 2007-006532-66	Sponsor Protocol Number: ZTV02C	Start Date*: 2008-03-25
Sponsor Name:Sanofi Pasteur MSD SNC
Full Title: An open-label, single-arm, phase IV study assessing the immunogenicity and safety of ZOSTAVAX at minimum release specification approaching expiry potency in subjects ≥50 years old
Medical condition: Not applicable_Healthy volunteers_Up to 50 years of age
Disease:
Population Age: Adults, Elderly		Gender: Male, Female
Trial protocol: FR (Completed)
Trial results: View results

EudraCT Number: 2006-005734-20

Sponsor Protocol Number: R076477-SCA-3002

Start Date*: 2008-04-24

Sponsor Name:Janssen L.P.

Full Title: A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Flexible Dose Paliperidone ER in the Treatment of Subjects with Schizoaffective Disorder

Medical condition: Schizoaffective disorder

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	8.1		10039621	Schizoaffective disorder	LLT

Population Age: Adults

Gender: Male, Female

Trial protocol: BG (Completed)

Trial results: View results

EudraCT Number: 2009-011337-27

Sponsor Protocol Number: AGMT Gastric-4

Start Date*: 2010-05-03

Sponsor Name:AGMT

Full Title: A two-stage multicenter phase II trial of concurrent induction chemoimmunotherapy with epirubicine, oxaliplatin, capecitabine and panitumumab in KRAS wild-type, resectable type II gastric adenoca...

Medical condition: Gastric cancer

Disease:	Version	SOC Term	Classification Code	Term	Level
	12.1		10017764	Gastric cancer stage II	LLT
	12.1		10017765	Gastric cancer stage III	LLT
	12.1		10017768	Gastric cancer stage IV without metastases	LLT

Population Age: Adults

Gender: Male, Female

Trial protocol: AT (Prematurely Ended)

Trial results: View results

EudraCT Number: 2004-000959-42	Sponsor Protocol Number: P03708	Start Date*: 2004-09-06
Sponsor Name:Integrated Therapeutics Group, Inc./Schering-Plough Oy
Full Title: Avoin, randomis., rinnakkaisryhmillä tehtävä monikeskustutk., jossa tutk. tehoa ja turvallisuutta vertailtaessa lääkityksen vaihtamista rosuvastatiiniin 10 mg päivässä verrattuna atorvastatiiniin...
Medical condition: Korkean riskin, erityisesti sepelvaltimotautia ja diabetesta sairastavat potilaat, joilla dieeti- ja liikuntaohjeista huolimatta Ldl-kolesteroli on yli suositusarvon 2.5 mmol/l. Suositusten mukaine...
Disease:
Population Age: Adults		Gender: Male, Female
Trial protocol: FI (Completed)
Trial results: View results

EudraCT Number: 2004-002577-23

Sponsor Protocol Number: CL2-20098-040

Start Date*: 2004-12-08

Sponsor Name:Institut de Recherches Internationales Servier

Full Title: Efficacy and safety of Agomelatine (25 mg with potential adjustment at 50 mg) given orally once a day for 12 weeks in out-patients with Generalised Anxiety Disorder. A randomised flexible dose doub...

Medical condition: Generalised Anxiety Disorder

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	3.3		10018075		P.T.

Population Age: Adults

Gender: Male, Female

Trial protocol: FI (Completed)

Trial results: View results

Subscribe to this Search
To subscribe to the RSS feed for this search click here

. This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.

Download Options:
Number of Trials to download:

Download Content:

Download Format:


Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.

Query did not match any studies.

For support, Contact us.

The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

European Medicines Agency © 1995-Tue May 06 09:52:09 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands

Austria
Belgium
Bulgaria
Croatia
Cyprus
Czechia
Denmark
Estonia
Finland
France
Germany
Greece
Hungary
Iceland
Ireland
Italy
Latvia
Liechtenstein
Lithuania
Luxembourg
Malta
Netherlands
Norway
Poland
Portugal
Romania
Slovakia
Slovenia
Spain
Sweden
United Kingdom
Outside EU/EEA